Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Quantum Genesis AI (QTZM) EBITDA (2016 - 2026)

Quantumzyme's EBITDA history spans 7 years, with the latest figure at -$1382.0 for Q1 2026.

  • For Q1 2026, EBITDA rose 94.37% year-over-year to -$1382.0; the TTM value through Jan 2026 reached -$126046.0, down 32.18%, while the annual FY2025 figure was -$180537.0, 10.36% down from the prior year.
  • EBITDA reached -$1382.0 in Q1 2026 per QTZM's latest filing, up from -$39196.0 in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$1382.0 in Q1 2026 to a low of -$60934.0 in Q4 2024.
  • Average EBITDA over 3 years is -$31511.5, with a median of -$31865.0 recorded in 2025.
  • Peak YoY movement for EBITDA: soared 35.67% in 2025, then surged 94.37% in 2026.
  • A 3-year view of EBITDA shows it stood at -$60934.0 in 2024, then skyrocketed by 35.67% to -$39196.0 in 2025, then soared by 96.47% to -$1382.0 in 2026.
  • Per Business Quant, the three most recent readings for QTZM's EBITDA are -$1382.0 (Q1 2026), -$39196.0 (Q4 2025), and -$24534.0 (Q1 2025).